Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer.

von Loga K, Woolston A, Punta M, Barber LJ, Griffiths B, Semiannikova M, Spain G, Challoner B, Fenwick K, Simon R, Marx A, Sauter G, Lise S, Matthews N, Gerlinger M.

Nat Commun. 2020 Jan 16;11(1):139. doi: 10.1038/s41467-019-13915-7.

PMID:
31949146
2.

Targeted drugs ramp up cancer mutability.

Gerlinger M.

Science. 2019 Dec 20;366(6472):1452-1453. doi: 10.1126/science.aaz9900. No abstract available.

PMID:
31857471
3.

[Improvement of antibiotic therapy adequacy with local guidelines and their reassessment through a multidisciplinary action: Prospective study in an Internal Medicine department].

Ourghanlian C, Caruba T, Facchin A, Hashemian S, Gerlinger MP, Sabatier B, Pouchot J, Lebeaux D, Michon A.

Rev Med Interne. 2020 Jan;41(1):8-13. doi: 10.1016/j.revmed.2019.09.002. Epub 2019 Nov 29. French.

PMID:
31791648
4.

Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.

Newey A, Griffiths B, Michaux J, Pak HS, Stevenson BJ, Woolston A, Semiannikova M, Spain G, Barber LJ, Matthews N, Rao S, Watkins D, Chau I, Coukos G, Racle J, Gfeller D, Starling N, Cunningham D, Bassani-Sternberg M, Gerlinger M.

J Immunother Cancer. 2019 Nov 18;7(1):309. doi: 10.1186/s40425-019-0769-8.

5.

Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer.

Woolston A, Khan K, Spain G, Barber LJ, Griffiths B, Gonzalez-Exposito R, Hornsteiner L, Punta M, Patil Y, Newey A, Mansukhani S, Davies MN, Furness A, Sclafani F, Peckitt C, Jiménez M, Kouvelakis K, Ranftl R, Begum R, Rana I, Thomas J, Bryant A, Quezada S, Wotherspoon A, Khan N, Fotiadis N, Marafioti T, Powles T, Lise S, Calvo F, Guettler S, von Loga K, Rao S, Watkins D, Starling N, Chau I, Sadanandam A, Cunningham D, Gerlinger M.

Cancer Cell. 2019 Jul 8;36(1):35-50.e9. doi: 10.1016/j.ccell.2019.05.013.

6.

Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma.

Davidson M, Barber LJ, Woolston A, Cafferkey C, Mansukhani S, Griffiths B, Moorcraft SY, Rana I, Begum R, Assiotis I, Matthews N, Rao S, Watkins D, Chau I, Cunningham D, Starling N, Gerlinger M.

Cancers (Basel). 2019 May 27;11(5). pii: E736. doi: 10.3390/cancers11050736.

7.

CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids.

Gonzalez-Exposito R, Semiannikova M, Griffiths B, Khan K, Barber LJ, Woolston A, Spain G, von Loga K, Challoner B, Patel R, Ranes M, Swain A, Thomas J, Bryant A, Saffery C, Fotiadis N, Guettler S, Mansfield D, Melcher A, Powles T, Rao S, Watkins D, Chau I, Matthews N, Wallberg F, Starling N, Cunningham D, Gerlinger M.

J Immunother Cancer. 2019 Apr 15;7(1):101. doi: 10.1186/s40425-019-0575-3.

8.

Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience.

Khan K, Rane JK, Cunningham D, Rao S, Watkins D, Starling N, Kalaitzaki E, Forster M, Braconi C, Valeri N, Gerlinger M, Chau I.

Clin Colorectal Cancer. 2019 Mar;18(1):64-71.e1. doi: 10.1016/j.clcc.2018.09.010. Epub 2018 Sep 29.

PMID:
30404764
9.

Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing.

Mansukhani S, Barber LJ, Kleftogiannis D, Moorcraft SY, Davidson M, Woolston A, Proszek PZ, Griffiths B, Fenwick K, Herman B, Matthews N, O'Leary B, Hulkki S, Gonzalez De Castro D, Patel A, Wotherspoon A, Okachi A, Rana I, Begum R, Davies MN, Powles T, von Loga K, Hubank M, Turner N, Watkins D, Chau I, Cunningham D, Lise S, Starling N, Gerlinger M.

Clin Chem. 2018 Nov;64(11):1626-1635. doi: 10.1373/clinchem.2018.289629. Epub 2018 Aug 27.

10.

Circulating tumour DNA, a promising biomarker for the management of colorectal cancer.

Khakoo S, Georgiou A, Gerlinger M, Cunningham D, Starling N.

Crit Rev Oncol Hematol. 2018 Feb;122:72-82. doi: 10.1016/j.critrevonc.2017.12.002. Epub 2017 Dec 16. Review.

PMID:
29458792
11.

Metastasis Seeding Cells: Lone Invaders or Mass Migrators?

Gerlinger M.

Clin Cancer Res. 2018 May 1;24(9):2032-2034. doi: 10.1158/1078-0432.CCR-17-3644. Epub 2018 Jan 31.

12.

Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice.

Moorcraft SY, Gonzalez de Castro D, Cunningham D, Jones T, Walker BA, Peckitt C, Yuan LC, Frampton M, Begum R, Eltahir Z, Wotherspoon A, Teixeira Mendes LS, Hulkki Wilson S, Gillbanks A, Baratelli C, Fotiadis N, Patel A, Braconi C, Valeri N, Gerlinger M, Rao S, Watkins D, Chau I, Starling N.

Ann Oncol. 2018 Jan 1;29(1):230-236. doi: 10.1093/annonc/mdx631.

PMID:
29361134
13.

Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study.

Kayhanian H, Goode E, Sclafani F, Ang JE, Gerlinger M, Gonzalez de Castro D, Shepherd S, Peckitt C, Rao S, Watkins D, Chau I, Cunningham D, Starling N.

Clin Colorectal Cancer. 2018 Mar;17(1):e69-e76. doi: 10.1016/j.clcc.2017.10.006. Epub 2017 Oct 16.

PMID:
29129559
14.

Cancer (r)evolution.

von Loga K, Gerlinger M.

Nat Ecol Evol. 2017 Aug;1(8):1051-1052. doi: 10.1038/s41559-017-0252-1. No abstract available.

PMID:
29046586
15.

Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters.

Linch M, Goh G, Hiley C, Shanmugabavan Y, McGranahan N, Rowan A, Wong YNS, King H, Furness A, Freeman A, Linares J, Akarca A, Herrero J, Rosenthal R, Harder N, Schmidt G, Wilson GA, Birkbak NJ, Mitter R, Dentro S, Cathcart P, Arya M, Johnston E, Scott R, Hung M, Emberton M, Attard G, Szallasi Z, Punwani S, Quezada SA, Marafioti T, Gerlinger M, Ahmed HU, Swanton C.

Ann Oncol. 2017 Oct 1;28(10):2472-2480. doi: 10.1093/annonc/mdx355.

16.

Classifying the evolutionary and ecological features of neoplasms.

Maley CC, Aktipis A, Graham TA, Sottoriva A, Boddy AM, Janiszewska M, Silva AS, Gerlinger M, Yuan Y, Pienta KJ, Anderson KS, Gatenby R, Swanton C, Posada D, Wu CI, Schiffman JD, Hwang ES, Polyak K, Anderson ARA, Brown JS, Greaves M, Shibata D.

Nat Rev Cancer. 2017 Oct;17(10):605-619. doi: 10.1038/nrc.2017.69. Epub 2017 Sep 15. Review.

17.

Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma.

Crusz SM, Tang YZ, Sarker SJ, Prevoo W, Kiyani I, Beltran L, Peters J, Sahdev A, Bex A, Powles T, Gerlinger M.

BMC Med. 2016 Nov 14;14(1):185.

18.

Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine.

Lipinski KA, Barber LJ, Davies MN, Ashenden M, Sottoriva A, Gerlinger M.

Trends Cancer. 2016 Jan;2(1):49-63. doi: 10.1016/j.trecan.2015.11.003. Epub 2016 Jan 29. Review.

19.

Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome.

Favero F, McGranahan N, Salm M, Birkbak NJ, Sanborn JZ, Benz SC, Becq J, Peden JF, Kingsbury Z, Grocok RJ, Humphray S, Bentley D, Spencer-Dene B, Gutteridge A, Brada M, Roger S, Dietrich PY, Forshew T, Gerlinger M, Rowan A, Stamp G, Eklund AC, Szallasi Z, Swanton C.

Ann Oncol. 2015 May;26(5):880-7. doi: 10.1093/annonc/mdv127. Epub 2015 Mar 2.

20.

SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair.

Kanu N, Grönroos E, Martinez P, Burrell RA, Yi Goh X, Bartkova J, Maya-Mendoza A, Mistrík M, Rowan AJ, Patel H, Rabinowitz A, East P, Wilson G, Santos CR, McGranahan N, Gulati S, Gerlinger M, Birkbak NJ, Joshi T, Alexandrov LB, Stratton MR, Powles T, Matthews N, Bates PA, Stewart A, Szallasi Z, Larkin J, Bartek J, Swanton C.

Oncogene. 2015 Nov 12;34(46):5699-708. doi: 10.1038/onc.2015.24. Epub 2015 Mar 2.

21.

Translating Seminoma Genomic Landscapes into Clinical Practice.

Gerlinger M.

Eur Urol. 2015 Jul;68(1):84-5. doi: 10.1016/j.eururo.2015.01.020. Epub 2015 Feb 2. No abstract available.

PMID:
25656809
22.

Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale.

Barber LJ, Davies MN, Gerlinger M.

Curr Opin Genet Dev. 2015 Feb;30:1-6. doi: 10.1016/j.gde.2014.12.001. Epub 2014 Dec 31. Review.

23.

Spatial and temporal diversity in genomic instability processes defines lung cancer evolution.

de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, Jamal-Hanjani M, Shafi S, Murugaesu N, Rowan AJ, Grönroos E, Muhammad MA, Horswell S, Gerlinger M, Varela I, Jones D, Marshall J, Voet T, Van Loo P, Rassl DM, Rintoul RC, Janes SM, Lee SM, Forster M, Ahmad T, Lawrence D, Falzon M, Capitanio A, Harkins TT, Lee CC, Tom W, Teefe E, Chen SC, Begum S, Rabinowitz A, Phillimore B, Spencer-Dene B, Stamp G, Szallasi Z, Matthews N, Stewart A, Campbell P, Swanton C.

Science. 2014 Oct 10;346(6206):251-6. doi: 10.1126/science.1253462.

24.

Cancer: evolution within a lifetime.

Gerlinger M, McGranahan N, Dewhurst SM, Burrell RA, Tomlinson I, Swanton C.

Annu Rev Genet. 2014;48:215-36. doi: 10.1146/annurev-genet-120213-092314. Epub 2014 Oct 1. Review.

PMID:
25292359
25.

The promise of circulating tumor cell analysis in cancer management.

Mateo J, Gerlinger M, Rodrigues DN, de Bono JS.

Genome Biol. 2014 Aug 30;15(8):448. doi: 10.1186/s13059-014-0448-5. Review.

26.

Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution.

Fisher R, Horswell S, Rowan A, Salm MP, de Bruin EC, Gulati S, McGranahan N, Stares M, Gerlinger M, Varela I, Crockford A, Favero F, Quidville V, André F, Navas C, Grönroos E, Nicol D, Hazell S, Hrouda D, O'Brien T, Matthews N, Phillimore B, Begum S, Rabinowitz A, Biggs J, Bates PA, McDonald NQ, Stamp G, Spencer-Dene B, Hsieh JJ, Xu J, Pickering L, Gore M, Larkin J, Swanton C.

Genome Biol. 2014 Aug 27;15(8):433. doi: 10.1186/s13059-014-0433-z.

27.

Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers.

Gulati S, Martinez P, Joshi T, Birkbak NJ, Santos CR, Rowan AJ, Pickering L, Gore M, Larkin J, Szallasi Z, Bates PA, Swanton C, Gerlinger M.

Eur Urol. 2014 Nov;66(5):936-48. doi: 10.1016/j.eururo.2014.06.053. Epub 2014 Jul 19.

28.

Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications.

Gerlinger M, Catto JW, Orntoft TF, Real FX, Zwarthoff EC, Swanton C.

Eur Urol. 2015 Apr;67(4):729-37. doi: 10.1016/j.eururo.2014.04.014. Epub 2014 May 2. Review.

PMID:
24836153
29.

Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing.

Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, Fisher R, McGranahan N, Matthews N, Santos CR, Martinez P, Phillimore B, Begum S, Rabinowitz A, Spencer-Dene B, Gulati S, Bates PA, Stamp G, Pickering L, Gore M, Nicol DL, Hazell S, Futreal PA, Stewart A, Swanton C.

Nat Genet. 2014 Mar;46(3):225-233. doi: 10.1038/ng.2891. Epub 2014 Feb 2.

30.

Computational optimisation of targeted DNA sequencing for cancer detection.

Martinez P, McGranahan N, Birkbak NJ, Gerlinger M, Swanton C.

Sci Rep. 2013 Dec 3;3:3309. doi: 10.1038/srep03309.

31.

The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer.

Sharpe K, Stewart GD, Mackay A, Van Neste C, Rofe C, Berney D, Kayani I, Bex A, Wan E, O'Mahony FC, O'Donnell M, Chowdhury S, Doshi R, Ho-Yen C, Gerlinger M, Baker D, Smith N, Davies B, Sahdev A, Boleti E, De Meyer T, Van Criekinge W, Beltran L, Lu YJ, Harrison DJ, Reynolds AR, Powles T.

Clin Cancer Res. 2013 Dec 15;19(24):6924-34. doi: 10.1158/1078-0432.CCR-13-1631. Epub 2013 Oct 15.

32.

Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas.

Gerlinger M, Quezada SA, Peggs KS, Furness AJ, Fisher R, Marafioti T, Shende VH, McGranahan N, Rowan AJ, Hazell S, Hamm D, Robins HS, Pickering L, Gore M, Nicol DL, Larkin J, Swanton C.

J Pathol. 2013 Dec;231(4):424-32. doi: 10.1002/path.4284.

33.

Acquired resistance to crizotinib from a mutation in CD74-ROS1.

Gerlinger M, Norton L, Swanton C.

N Engl J Med. 2013 Sep 19;369(12):1172-3. doi: 10.1056/NEJMc1309091. No abstract available.

PMID:
24047073
34.

Parallel evolution of tumour subclones mimics diversity between tumours.

Martinez P, Birkbak NJ, Gerlinger M, McGranahan N, Burrell RA, Rowan AJ, Joshi T, Fisher R, Larkin J, Szallasi Z, Swanton C.

J Pathol. 2013 Aug;230(4):356-64. doi: 10.1002/path.4214.

PMID:
23716380
35.

Prognostic and predictive markers in metastatic renal cell carcinoma.

Khattak MA, Bakr F, Krzystanek M, Szallasi Z, Gerlinger M, Santos C, Swanton C, Pickering LM, Gore ME, Larkin JM.

J Clin Oncol. 2013 Mar 1;31(7):971-2. doi: 10.1200/JCO.2012.46.9353. Epub 2013 Jan 7. No abstract available.

PMID:
23295806
36.

Intratumor heterogeneity: seeing the wood for the trees.

Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C.

Sci Transl Med. 2012 Mar 28;4(127):127ps10. doi: 10.1126/scitranslmed.3003854.

PMID:
22461637
37.

Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C.

N Engl J Med. 2012 Mar 8;366(10):883-892. doi: 10.1056/NEJMoa1113205. Erratum in: N Engl J Med. 2012 Sep 6;367(10):976.

38.

Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target.

Gerlinger M, Santos CR, Spencer-Dene B, Martinez P, Endesfelder D, Burrell RA, Vetter M, Jiang M, Saunders RE, Kelly G, Dykema K, Rioux-Leclercq N, Stamp G, Patard JJ, Larkin J, Howell M, Swanton C.

J Pathol. 2012 Jun;227(2):146-56. doi: 10.1002/path.4006. Epub 2012 Apr 18. Erratum in: J Pathol. 2015 Aug;236(4):531.

39.

False positive galactomannan Platelia due to piperacillin-tazobactam.

Gerlinger MP, Rousselot P, Rigaudeau S, Billon C, Touratier S, Castaigne S, Eloy O.

Med Mal Infect. 2012 Jan;42(1):10-4. doi: 10.1016/j.medmal.2011.10.018. Epub 2011 Dec 5.

PMID:
22153703
40.

How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine.

Gerlinger M, Swanton C.

Br J Cancer. 2010 Oct 12;103(8):1139-43. doi: 10.1038/sj.bjc.6605912. Epub 2010 Sep 28. Review.

41.

Elevated LDH predicts poor outcome of recurrent germ cell tumours treated with dose dense chemotherapy.

Gerlinger M, Wilson P, Powles T, Shamash J.

Eur J Cancer. 2010 Nov;46(16):2913-8. doi: 10.1016/j.ejca.2010.07.004. Epub 2010 Aug 13.

PMID:
20709529
42.

Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets.

Swanton C, Larkin JM, Gerlinger M, Eklund AC, Howell M, Stamp G, Downward J, Gore M, Futreal PA, Escudier B, Andre F, Albiges L, Beuselinck B, Oudard S, Hoffmann J, Gyorffy B, Torrance CJ, Boehme KA, Volkmer H, Toschi L, Nicke B, Beck M, Szallasi Z.

Genome Med. 2010 Aug 11;2(8):53. doi: 10.1186/gm174.

43.

Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference.

Tan DS, Gerlinger M, Teh BT, Swanton C.

Eur J Cancer. 2010 Aug;46(12):2166-77. doi: 10.1016/j.ejca.2010.03.019. Epub 2010 Apr 21. Review.

PMID:
20413300
44.

Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials.

Juul N, Szallasi Z, Eklund AC, Li Q, Burrell RA, Gerlinger M, Valero V, Andreopoulou E, Esteva FJ, Symmans WF, Desmedt C, Haibe-Kains B, Sotiriou C, Pusztai L, Swanton C.

Lancet Oncol. 2010 Apr;11(4):358-65. doi: 10.1016/S1470-2045(10)70018-8. Epub 2010 Feb 26.

45.

Surveillance investigations after high-dose therapy with stem cell rescue for recurrent follicular lymphoma have no impact on management.

Gerlinger M, Rohatiner AZ, Matthews J, Davies A, Lister TA, Montoto S.

Haematologica. 2010 Jul;95(7):1130-5. doi: 10.3324/haematol.2009.020115. Epub 2010 Jan 27.

46.

Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patients.

Walton SM, Gerlinger M, de la Rosa O, Nuber N, Knights A, Gati A, Laumer M, Strauss L, Exner C, Schäfer N, Urosevic M, Dummer R, Tiercy JM, Mackensen A, Jaeger E, Lévy F, Knuth A, Jäger D, Zippelius A.

J Immunol. 2006 Dec 1;177(11):8212-8.

47.

Egr-1 induces the expression of its corepressor nab2 by activation of the nab2 promoter thereby establishing a negative feedback loop.

Kumbrink J, Gerlinger M, Johnson JP.

J Biol Chem. 2005 Dec 30;280(52):42785-93. Epub 2005 Oct 31.

Supplemental Content

Loading ...
Support Center